Category Archives: Uncategorized

Subscribe to Uncategorized RSS Feed

USPTO Examination Time Goals -- How Much Time Should Examiners Have To Examine A Patent Application?

As part of its ongoing efforts to improve patent quality, the USPTO is reevaluating its examination time goals and seeking public feedback on how much time examiners should have to examine a patent application. Examination time goals already vary by technology and the examiner’s level of experience, but should the USPTO refine the goals to … Continue reading this entry

USPTO Makes It Easy To Review Patent Assignment Documents

The USPTO has yet to implement new rules requiring applicants to promptly record patent ownership information, but it recently made it much easier to review patent assignment documents that have been recorded at the USPTO. The USPTO previously provided ownership information on its patent assignment database website, but now provides PDF images of the actual recorded documents–such … Continue reading this entry

Judge Grants Gilead Motion To Invalidate Remicade Patent For Obviousness-Type Double Patenting

The FDA approved Inflectra–Celltrion’s biosimilar version of Janssen’s Remicade® (infliximab) product–in April 2016, but according to Pfizer’s press release it’s commercial launch still “depend[s] on a number of factors” including “intellectual property considerations.” The pending biosimilar patent litigation got one step closer to resolution last week when Judge Wolf of the U.S. District Court for the District of Massachusetts … Continue reading this entry

The Value Of Prophetic Examples

In Allergan, Inc. v. Sandoz, Inc., the Federal Circuit affirmed the district court decision that upheld the validity of the Allergan patents relating to Lumigan® 0.01% glaucoma eye drops against obviousness, written description, and enablement challenges. I previously wrote about the obviousness analysis. Here, I look at the court’s discussion of the written description and enablement … Continue reading this entry

Put PharmaPatents In The Blawg 100

If you are reading this, then you probably rely on PharmaPatents for timely insight on emerging legal developments impacting patent rights in the pharmaceutical, biotechnology, and chemical fields. I would really appreciate it if you would show your support by nominating PharmaPatentsfor the ABA Journal’s Blawg 100. The nomination form has nine fields, and I can … Continue reading this entry

The USPTO Is Off-Key With International Patent Law Harmonization

As a leader in science, technology and innovation, the United States long has played a central role in global intellectual property matters. As the world’s largest economy, the United States has played a central role in trade policy, including its role in setting up the TRIPS agreements that made intellectual property rights a precondition for joining … Continue reading this entry